阿托伐他汀对胆固醇达标不稳定性心绞痛合并2型糖尿病患者疗效观察

Observation of Curative Effects of Atorvastatin in Patients with Cholesterol Below The Target Level and Unstable Angina Pectoris With Type 2 Diabetes

目的观察阿托伐他汀对胆固醇达标不稳定性心绞痛合并2型糖尿病患者的临床疗效和血脂变化。方法将57例合并2型糖尿病的血脂达标〔低密度脂蛋白胆固醇(LDL-C)<2.07mmol/L〕的不稳定性心绞痛患者分为两组:治疗组29例,予阿托伐他汀20mg,1次/日口服;对照组28例,除不服阿托伐他汀外,其他治疗同治疗组。观察8周后两组患者的心绞痛和心电图疗效以及血脂变化。结果 8周后治疗组心绞痛总有效27例,对照组总有效19例,治疗组总有效率显著高于对照组(P<0.05);治疗前静息心电图有ST-T改变者50例,治疗组24例,总有效15例,对照组26例,总有效9例,治疗组心电图改善总有效率显著高于对照组(P<0.05);治疗组LDL-C水平明显下降,与治疗前比较差异有统计学意义(P<0.05),与对照组同期比较也差异有统计学意义(P<0.05)。结论阿托伐他汀可明显改善胆固醇达标不稳定性心绞痛合并2型糖尿病患者的心绞痛症状和心电图,对血脂达标者仍有降脂作用。

Objective To observe the clinical curative effects and blood lipid change of atorvastatin in patients with cholesterol below the target level and unstable angina pectoris with type 2 diabetes.Methods Divide fifty-seven type 2 diabetes mellitus patients with unstable angina pectoris and blood cholesterol below the target level[low density lipoprotein-cholesterol（LDL-C）2.07mmol/L]into two groups.Patient in treated group（n=29）took orally atorvastatin（20mg）once a day.Patient in control group（n=28）had the same treatment as in treated group with the exception of taking orally atorvastation.Routine treatment of unstable angina pectoris and glucose-lowering medicine treatment were provided for all the patients.To observe the curative effects of unstable angina pectoris and electrocardiogram and changes of blood lipid after eight weeks of the two groups.Results Curative effects of unstable angina pectoris and electrocardiogram in treated group was significantly increased compared with control group after eight weeks（P0.05）.LDL-C level in treated group was significantly decreased and had a significant difference compared that of pretherapy（P0.05）.The treated group also had a significant compared with the same period of control group（P0.05）.Conclusion Atorvastatin could significantly improve the curative effects of unstable angina pectoris and electrocardiogram in patients with cholesterol below the target level and unstable angina pectoris with type 2 diabetes and could also reduce blood cholesterol in patients with blood cholesterol below the target level.